ArticleAllergy2021
Immune changes beyond Th2 pathways during rapid multifood immunotherapy enabled with omalizumab.
Article in Allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02643862 (Randomized, Controlled, Blinded, Pilot Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Controlled, Blinded, Pilot Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Understanding the Variability of Peanut-Oral Immunotherapy Responses by Multi-Omics Profiling of Immune Cells.Allergy · 2025Trial
- HLA-DRAllergy · 2025Trial
- CD8Nature communications · 2022Trial
- Peanut oral immunotherapy differentially suppresses clonally distinct subsets of T helper cells.The Journal of clinical investigation · 2022Trial
- Bioassays in Allergy: Technical Characteristics, Limitations, and Pathways to Clinical Implementation-An EAACI Position Paper.Clinical and translational allergy · 2026Review
- Off-label applications of omalizumab: Current insights and perspectives.The World Allergy Organization journal · 2025Review
- Biologics in IgE-mediated food allergy: A systematic review and meta-analysis of interventional studies.The World Allergy Organization journal · 2025Review
- New insights into the mechanisms of childhood food allergies.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Review
- Role of allergen immunotherapy and biologics in allergic diseases.Current opinion in immunology · 2024Review
- Effects of Flavourzyme and Alkaline Protease Treatment on Structure and Allergenicity of Peanut Allergen Ara h 1.Food technology and biotechnology · 2024Article
- Mass Cytometry in Food Allergy Research.Methods in molecular biology (Clifton, N.J.) · 2024Article
- The origins and longevity of IgE responses as indicated by serological and cellular studies in mice and humans.Allergy · 2023Review
- Treatment of food allergy: Oral immunotherapy, biologics, and beyond.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2023Review
- Immune signatures predicting the clinical outcome of peanut oral immunotherapy: where we stand.Frontiers in allergy · 2023Review
- Cytometric analysis reveals an association between allergen-responsive natural killer cells and human peanut allergy.The Journal of clinical investigation · 2022Article
- Mechanisms and biomarkers of successful allergen-specific immunotherapy.Asia Pacific allergy · 2022Review
- The rationale for development of ligelizumab in food allergy.The World Allergy Organization journal · 2022Review
- Combining Anti-IgE Monoclonal Antibodies and Oral Immunotherapy for the Treatment of Food Allergy.Clinical reviews in allergy & immunology · 2022Review
- Oral Immunotherapy for Food-Allergic Children: A Pro-Con Debate.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundMultifood oral immunotherapy (mOIT) with adjunctive anti-IgE (omalizumab, XOLAIR
methodsParticipants in our phase 2 mOIT trial (NCT02643862) received omalizumab from baseline to week 16 and mOIT from week 8 to week 36. We compared the immune profile of PBMCs and plasma taken at baseline, week 8, and week 36 using high-dimensional mass cytometry, component-resolved diagnostics, the indirect basophil activation test, and Luminex.
resultsWe found (i) decreased frequency of IL-4
conclusionsThis exploratory study provides novel comprehensive insight into the immune underpinnings of desensitization through omalizumab-facilitated mOIT. Moreover, this study provides encouraging results to support the complex immune changes that can be induced by OIT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.